Analysts’ Perspective: bluebird bio (BLUE), Michael Kors (KORS), Wyndham Destinations (WYND)

Investment Analysts at Cantor Fitzgerald upgrade bluebird bio, Inc. (NASDAQ:BLUE) shares from Underweight to Neutral rating while increasing their price target from $122 to $134.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer.


Brokerage Firm UBS upgraded Michael Kors Holdings Limited (NYSE:KORS) shares from Neutral to Buy rating.

Michael Kors Holdings Limited design, markets, distributes, and retails branded women’s and men’s apparel and accessories.


Wyndham Destinations, Inc. (NYSE:WYND) shares were upgraded by analysts at Macquarie from Underperform to Neutral rating.

Wyndham Destinations, Inc. operates as a vacation ownership and exchange company.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at